Cost Still the Biggest Barrier for GLP-1 Access, Navitus Survey Finds
A Navitus Pulse Survey of 2,000 Americans found that cost remains the biggest barrier to GLP-1 use, with 68% saying it influenced their decision to start or continue treatment, 44% reporting cost was higher than expected and nearly a quarter paying over $250 per prescription fill. Navitus Chief Pharmacy Officer, Sharon Faust, PharmD, MBA, shared a comment on the ongoing concerns that may rise as GLP-1 utilization increases.
MORE ABOUT Sharon Faust, PharmD, MBA, CSP
Sharon Faust is the Chief Pharmacy Officer at Navitus Health Solutions. She oversees Health Strategies, Provider Services and Lumicera Health Services. She is a licensed pharmacist in Wisconsin and is on the Board of Directors for the National Association of Specialty Pharmacy and the Drug Selection Advisory Committee for CivicaScript®. In 2023, she was awarded the Top 50 Most Influential Leaders in Pharmacy Award presented by the Pharmacy Podcast network.
Stay Informed and Connected
Receive expert insights, healthcare tips, and important updates on pharmacy benefits, drug recalls, and more—straight to your inbox.
CLARITY FOR ACTION
Gain Clarity: Navitus 10th Annual Drug Trend Report Ready to Download
Our 2025 report provides transparent, data-driven insight to help plans, plan sponsors and consultants navigate an increasingly complex prescription drug landscape.
Related blogs
Navigating Healthcare and Improving Outcomes
Don’t Sign Here – The 7 Red Flags of PBM Contracts
Signing with a new pharmacy benefit manager (PBM) can be a daunting experience, with hundreds or thousands of plan members depending on that choice. And in this opaque industry, it is important to look beyond the initial conversations with a PBM when…
